The study brings together results from animal models, in vitro tests with human semen, and a first pilot clinical trial. It shows that HyperSperm improves the number of usable embryos and demonstrates an extremely high safety profile. Thanks to HyperSperm, more couples are expected to achieve successful pregnancies after assisted reproduction treatments.
“The publication of our pilot study in a high-impact journal endorses our technology,” says Dr. Rita Vassena, CEO of Fecundis. “HyperSperm reproduces in the laboratory the changes that occur in the female tract during natural fertilization, and this translates into more high-quality embryos and, potentially, faster and more successful treatments for patients.”
The study included a clinical trial involving 10 couples undergoing IVF with donor eggs. The group treated with HyperSperm experienced a more than 50% increase in the number of embryos available for treatment. This could represent a paradigm shift in the way we approach sperm preparation, a traditionally underestimated stage of the IVF process.
In addition to its clinical benefits, the technology has a robust safety profile, supported by animal studies that demonstrate healthy and fertile offspring up to the second generation.
“One of the main challenges of assisted reproduction is that most patients can’t afford more than one or two attempts,” explains Dr. Vassena. “If we can increase the number of quality embryos from the start, we reduce the number of cycles required, the costs, and the emotional strain on patients. HyperSperm can help more people successfully complete their treatment.”
Fecundis will continue expanding clinical studies both in Europe and internationally over the coming months, with the goal of validating the results in larger patient cohorts and moving toward incorporating the technique into fertility clinics.
Fecundis is a clinical-stage medical technology company focused on developing innovative solutions to increase the success of assisted reproduction. Founded by international experts in sperm biology and reproductive medicine, the company is headquartered in the Barcelona Science Park and Argentina. Its flagship product, HyperSperm, sets a new standard in sperm preparation based on solid scientific evidence and a focused approach to improving access to and effectiveness of fertility treatments.
Article of reference: Gómez-Elías MD et al. Frontiers in Cell and Developmental Biology. doi: 10.3389/fcell.2025.1596421
Image: Fecundis team, based in Barcelona Science Park. Photo / Fecundis
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Proceeds to support clinical development of lead first-in-class progra...
